A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Recruiting
Phase 3Interventional Study
Bipolar DisorderBipolar DepressionBipolar I DisorderBipolar II Disorder
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 – 74
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
400 (estimated)
Sponsor
Xenon Pharmaceuticals Inc. · Industry
Who this trial is looking for
This trial is looking for adults aged 18 to 74 who are currently experiencing a depressive episode connected to bipolar disorder. Participants will receive either azetukalner or a placebo to see how well it works and its safety.
Are You a Good Fit for This Trial?
Must not be takingAntidepressantsMood stabilizersAnticonvulsantsAntipsychotics
You may be able to join if
I am between 18 and 74 years old.
I had my first major depressive episode before I turned 50.
My Body Mass Index (BMI) is between 18 and 40.
I have been diagnosed with bipolar I or II disorder.
I am currently in a depressive episode lasting between 4 weeks and 12 months.
You may not be able to join if
I have a diagnosis of any major depressive disorder.
I have a non-bipolar psychiatric condition.
I have a substance use disorder in the past 6 months.
I have had a significant eating disorder in the last 12 months.
I had a young mania rating score above 12 at my screening.
I was hospitalized for mania in the last 30 days.
I have been treatment-resistant in my current depressive episode.
I have had active suicidal thoughts or behaviors in the past 6 months.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Key Inclusion Criteria:
* Adults ≥18 and ≤74 years of age who experienced their first major depressive episode (MDE) prior to 50 years of age.
* Body Mass Index (BMI) ≥18 kg/m2 and ≤40 kg/m2.
* Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) …
Key Inclusion Criteria:
* Adults ≥18 and ≤74 years of age who experienced their first major depressive episode (MDE) prior to 50 years of age.
* Body Mass Index (BMI) ≥18 kg/m2 and ≤40 kg/m2.
* Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for bipolar I or II disorder and is currently in a MDE, confirmed using the Mini International Neuropsychiatric Interview (MINI).
* Current MDE must has a duration of ≥4 weeks and ≤12 months.
Key Exclusion Criteria:
* Participant has any type of major depressive disorder (MDD) diagnosis, including MDD with psychotic features, MDD with catatonia, MDD with seasonal pattern, or postpartum depression.
* Participant has any nonbipolar psychiatric diagnosis.
* Participant has a substance use disorder (excluding tobacco) within the 6 months prior to screening visit.
* Participant has a symptomatic eating disorder within the 12 months prior to screening visit.
* Participant has a Young Mania Rating Scale (YMRS) score \>12 points at screening visit or randomization.
* Participant has been hospitalized for mania within the 30 days prior to screening visit.
* Participant is considered treatment-resistant in the current bipolar depressive episode, defined as having treatment resistance (no remission) to ≥2 different medications approved by the regional regulatory authority at an adequate dose (per regulatory approved label) and for an adequate duration (at least 6 weeks).
* Participant has had an active suicidal plan/intent within the 6 months prior to screening, presence of suicidal behavior in the last 12 months.
* Participant has self-injurious behavior without intent to die in the 12 months prior to screening.
* Participant has used antidepressants, mood stabilizers, anticonvulsants, antipsychotics, or other prohibited medications within the 1 week or within a period less than 5 times the drug's half-life, whichever is longer prior to randomization.
* Participants with medical conditions that may interfere with the purpose or conduct of the study.
* Participant is pregnant, breastfeeding, or planning to become pregnant.
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.